Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please in Korean Patients With Coronary In-stent Restenosis

Inclusion Criteria: * Age ≥19 years old * Patients with significant coronary artery stenosis including left main coronary lesion (\> 50% diameter stenosis on coronary angiography) * Patients with stable angina pectoris, or unstable angina pectoris, and asymptomatic myocardial ischemia * Patients suitable to receive coronary revascularization of any type * Restenosis Mehran type I-III after stent implantation for the first time * Patients with In-stent restenosis after 90 days of the stent implantation, and the degree of restenosis corresponds to Mehran type I-Ⅲ. * Diameter of the stent with restenosis should be 2.0-4.0mm (included). Length of the stenosis lesion should be no more than 40mm * In case of voluntarily deciding to participate in this clinical trial by signing the informed consent form Exclusion Criteria: * Patients with Infarct related artery (IRA) lesions among patients with acute myocardial infarction * Patients have restenosis lesions with thrombosis * Patients with a history of cardiogenic shock * Patients with total occlusion indicating TIMI 0 blood flow at the target lesion (Mehran type IV stenosis) * Patients with graft vessel lesion * Patients who are contraindicated in aspirin, heparin, clopidogrel, ticlopidine, and paclitaxel * Patients with renal insufficiency (eGFR\<30mL/min) * Pregnant or lactating women * The patients have a life expectancy of less than 12 months * Patients who had reduced immunity or clinically significant abnormalities in the laboratory tests (hematological, serum biochemical, and urine tests) performed at the time of screening * Patients who had clinically significant disorders in cardiovascular system, digestive system, respiratory system, endocrine system, and central nervous system, or mental illness that significantly affects this study * Patients who are unsuitable for the study according to the investigator judges